Mark Yackley, MD
Internal Medicine · Hutchinson, KSNPI 1356347215
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.9%), consulting fees and education — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Pfizer at 51.8% of the total. Reporting peaked in 2020 at $4,807 and has fallen 80.1% since, to $957 in 2025. Among internal medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 438 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- Novo Nordisk$1K
- Amgen$945
- AbbVie$611
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$239
- Lilly USA, LLC$177
- plus $2K from 32 others
What the payments were for
- Consulting fees$4,75146%
- Food & beverage$5,44153%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 75 | $5,332 |
| Novo Nordisk | 87 | $1,050 |
| Amgen | 68 | $945 |
| AbbVie | 58 | $611 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $239 |
| Lilly USA, LLC | 11 | $177 |
| Bayer | 12 | $168 |
| Daiichi Sankyo Inc. | 8 | $151 |
| Abbott | 15 | $145 |
| Novartis | 12 | $144 |
| Astellas Pharma US Inc | 6 | $138 |
| Xeris Pharmaceuticals, Inc. | 5 | $103 |
| Abiomed | 4 | $97 |
| Sanofi-aventis U.S. LLC | 6 | $93 |
| Sumitomo Pharma America, Inc. | 6 | $93 |
| Merck | 5 | $80 |
| Boehringer Ingelheim | 4 | $70 |
| Sunovion Pharmaceuticals Inc. | 3 | $65 |
| Idorsia Pharmaceuticals US Inc | 4 | $64 |
| GSK | 3 | $51 |
| AstraZeneca(2 entities) | 3 | $47 |
| Sanofi Pasteur Inc. | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $45 |
| Phathom Pharmaceuticals, Inc. | 4 | $42 |
| Inspire Medical Systems, Inc. | 2 | $40 |
| Johnson & Johnson | 3 | $38 |
| Strongbridge US Inc. | 2 | $34 |
| Cequr Corporation | 1 | $24 |
| Insulet Corporation | 1 | $19 |
| Mylan Specialty L.p. | 1 | $17 |
| Radius Health, Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Corium, LLC | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
How this compares
$10,293 in reported general payments places this provider in the 95th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 164 | $169,078 |
| EliquisApixaban | 200 | $128,238 |
| MounjaroTirzepatide | 85 | $99,212 |
| JardianceEmpagliflozin | 96 | $79,942 |
| Humira PenAdalimumab | 11 | $71,580 |
| JanuviaSitagliptin Phosphate | 86 | $66,686 |
| Xeljanz XrTofacitinib Citrate | 27 | $62,401 |
| TrulicityDulaglutide | 51 | $52,629 |
| XareltoRivaroxaban | 65 | $46,947 |
| Tresiba Flextouch U-200Insulin Degludec | 48 | $36,715 |
| GemtesaVibegron | 80 | $33,785 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $33,481 |
| MyrbetriqMirabegron | 60 | $31,419 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $30,130 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $28,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,050 | $169,078164 claims |
| Lilly USA, LLCMounjaro, Trulicity | $177 | $151,841136 claims |
| PfizerEliquis, Premarin | $5,332 | $138,613219 claims |
| Boehringer IngelheimJardiance | $70 | $79,94296 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $51 | $68,726119 claims |
| MerckJanuvia | $80 | $66,68686 claims |
| AbbVieCreon, Linzess | $611 | $50,77355 claims |
| Johnson & JohnsonXarelto | $38 | $46,94765 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $93 | $33,78580 claims |
| Astellas Pharma US IncMyrbetriq | $138 | $31,41960 claims |
| AstraZenecaFarxiga, Symbicort | $47 | $24,30958 claims |
| BayerKerendia | $168 | $17,99028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Hutchinson
- Michael GreenHutchinson$7K
- Sara PatryHutchinson$5K
- Shadi HamdehKansas City$959K
- Donna GriebelLawrence$781K
- Lucas PittsKansas City$235K
- Donna SweetWichita$185K
- Wissam SalibaWichita$155K
- Mark HamblinKansas City$147K
- Atieh JibbeWichita$121K
- Herbert WaxmanOverland Park$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.